This GHRP-6 + CJC-1295 with DAC peptide blend contains 1.5 mg of GHRP-6 and 0.6 mg of CJC-1295 with DAC, supporting controlled laboratory research on pituitary activation and growth hormone response pathways. GHRP-6 is a growth hormone secretagogue studied for its stimulation of GHSR-driven pituitary signaling and targeted GH release. CJC-1295 with DAC features a Drug Affinity Complex designed to extend the duration of GHRH receptor engagement, enabling prolonged exposure models in research environments.
Researchers value this dual-peptide formulation because it enables mechanistic investigation of combined GH-axis stimulation, pairing selective GHSR activation with long-lasting GHRH signaling. The GHRP-6 + CJC-1295 with DAC peptide blend supports studies exploring timing effects, receptor sensitivity, and comparative outcomes between transient and sustained GH release.
Typical research applications include:
Analysing pituitary GH secretion patterns under dual signaling
Mapping GHRH vs. GHSR receptor interaction profiles
Studying duration-dependent endocrine responses in vitro or ex vivo
Benchmarking combination models against single-peptide controls
Both components demonstrate clear, reproducible behavior in controlled systems, making this blend suitable for structured GH-axis experiments requiring precise monitoring of dose and timing variables.
This product is supplied strictly as a high-purity laboratory reagent for professional scientific research. It is not approved for human or veterinary administration, therapeutic use, diagnostic procedures, or any clinical application. All handling must comply with laboratory safety standards and applicable regulatory guidelines.
For research use only. Not for human consumption.
Researchers value this dual-peptide formulation because it enables mechanistic investigation of combined GH-axis stimulation, pairing selective GHSR activation with long-lasting GHRH signaling. The GHRP-6 + CJC-1295 with DAC peptide blend supports studies exploring timing effects, receptor sensitivity, and comparative outcomes between transient and sustained GH release.
Typical research applications include:
Analysing pituitary GH secretion patterns under dual signaling
Mapping GHRH vs. GHSR receptor interaction profiles
Studying duration-dependent endocrine responses in vitro or ex vivo
Benchmarking combination models against single-peptide controls
Both components demonstrate clear, reproducible behavior in controlled systems, making this blend suitable for structured GH-axis experiments requiring precise monitoring of dose and timing variables.
This product is supplied strictly as a high-purity laboratory reagent for professional scientific research. It is not approved for human or veterinary administration, therapeutic use, diagnostic procedures, or any clinical application. All handling must comply with laboratory safety standards and applicable regulatory guidelines.
For research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
